Ind-Swift (INDSWFTLAB) | Financial Analysis & Statements
Ind-Swift Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
5.1B
Gross Profit
2.1B
41.64%
Operating Income
-48.6M
-0.96%
Net Income
2.5B
49.05%
Balance Sheet Metrics
Total Assets
14.4B
Total Liabilities
2.7B
Shareholders Equity
11.7B
Debt to Equity
0.23
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2025
Ind-Swift Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5.6B | 12.8B | 12.1B | 10.4B | 8.9B |
| Cost of Goods Sold | 3.4B | 7.6B | 7.7B | 6.3B | 5.2B |
| Gross Profit | 2.2B | 5.2B | 4.4B | 4.1B | 3.8B |
| Gross Margin % | 39.8% | 40.5% | 36.5% | 39.4% | 42.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | 327.2M | 330.1M |
| Selling, General & Administrative | 1.1B | 795.8M | 635.8M | 644.1M | 481.1M |
| Other Operating Expenses | 97.9M | 335.3M | 100.3M | 83.1M | 40.7M |
| Total Operating Expenses | 1.2B | 1.1B | 736.0M | 1.1B | 852.0M |
| Operating Income | -416.4M | 2.2B | 1.8B | 924.2M | 1.1B |
| Operating Margin % | -7.4% | 16.8% | 15.0% | 8.9% | 12.4% |
| Non-Operating Items | |||||
| Interest Income | 382.7M | 183.7M | 58.7M | 5.6M | 5.1M |
| Interest Expense | 13.8M | 466.9M | 863.9M | 914.5M | 933.5M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 2.6B | 5.8B | 865.2M | 125.3M | 180.1M |
| Income Tax | 72.7M | 1.6B | 386.9M | 146.8M | 211.6M |
| Effective Tax Rate % | 2.8% | 27.6% | 44.7% | 117.1% | 117.5% |
| Net Income | 2.5B | 4.2B | 476.0M | -21.5M | -31.5M |
| Net Margin % | 44.6% | 32.9% | 3.9% | -0.2% | -0.4% |
| Key Metrics | |||||
| EBITDA | 317.3M | 2.9B | 2.6B | 2.5B | 2.0B |
| EPS (Basic) | ₹37.25 | ₹71.24 | ₹-4.28 | ₹-4.28 | ₹-4.28 |
| EPS (Diluted) | ₹35.21 | ₹71.24 | ₹-4.28 | ₹-4.28 | ₹-4.28 |
| Basic Shares Outstanding | 67243863 | 59086860 | 59086860 | 59086865 | 59086860 |
| Diluted Shares Outstanding | 67243863 | 59086860 | 59086860 | 59086865 | 59086860 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Ind-Swift Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 4.1B | 4.3B | 182.0M | 214.8M | 116.0M |
| Short-term Investments | 393.7M | - | 49.5M | 118.9M | 83.0M |
| Accounts Receivable | 1.6B | 1.7B | 5.1B | 4.5B | 4.3B |
| Inventory | 1.1B | 104.6M | 4.4B | 4.3B | 3.8B |
| Other Current Assets | 1.1B | 1.0K | 1.0K | 1.0K | 680.9M |
| Total Current Assets | 8.7B | 6.6B | 11.6B | 10.8B | 9.4B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 270.2M | 51.0K | 476.9M | 471.3M | 459.3M |
| Goodwill | 106.8M | 0 | 0 | 10.4M | 96.2M |
| Intangible Assets | 106.8M | - | - | 10.0M | 92.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.0K | 4.0K | -2.0K | -1.0K | -2.0K |
| Total Non-Current Assets | 5.7B | 5.0B | 6.6B | 7.3B | 8.7B |
| Total Assets | 14.4B | 11.7B | 18.2B | 18.0B | 18.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.1B | 939.8M | 2.0B | 1.8B | 1.4B |
| Short-term Debt | 149.2M | 54.6M | 1.1B | 1.0B | 1.2B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 40.6M | 84.1M | 102.4M | 89.0M | 127.2M |
| Total Current Liabilities | 2.2B | 2.2B | 3.7B | 3.3B | 3.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 259.3M | 111.6M | 7.5B | 8.5B | 8.8B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.0K | - | 1.0K | -1.0K | 1.7M |
| Total Non-Current Liabilities | 447.9M | 123.9M | 7.7B | 8.7B | 9.0B |
| Total Liabilities | 2.7B | 2.3B | 11.4B | 12.0B | 12.2B |
| Equity | |||||
| Common Stock | 687.4M | 590.9M | 598.1M | 598.1M | 598.1M |
| Retained Earnings | -1.4B | 3.9B | -293.3M | -780.5M | -762.4M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 11.7B | 9.3B | 6.8B | 6.0B | 6.0B |
| Key Metrics | |||||
| Total Debt | 408.6M | 166.2M | 8.6B | 9.5B | 10.1B |
| Working Capital | 6.4B | 4.4B | 7.9B | 7.4B | 6.3B |
Balance Sheet Composition
Ind-Swift Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 345.9M | 2.0B | 1.1B | 125.3M | 180.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -197.6M | -4.8B | -513.3M | -879.2M | -624.1M |
| Operating Cash Flow | -213.5M | -2.6B | 1.4B | 125.7M | 458.3M |
| Investing Activities | |||||
| Capital Expenditures | -258.1M | -415.7M | -126.3M | -129.2M | -39.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -258.1M | -415.7M | -126.3M | -129.2M | -39.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 276.0M | - | - | 0 | 0 |
| Debt Repayment | -66.0M | -374.3M | -459.1M | -360.1M | -398.5M |
| Financing Cash Flow | 1.1B | 8.2B | -571.3M | -360.1M | -398.5M |
| Free Cash Flow | -898.8M | -2.1B | 1.8B | 1.3B | 1.3B |
| Net Change in Cash | 639.5M | 5.2B | 697.2M | -363.6M | 20.7M |
Cash Flow Trend
Ind-Swift Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
4.00
Price to Book
0.84
Price to Sales
2.02
PEG Ratio
0.05
Profitability Ratios
Profit Margin
41.86%
Operating Margin
-3.09%
Return on Equity
21.35%
Return on Assets
17.41%
Financial Health
Current Ratio
4.03
Debt to Equity
1.69
Beta
0.67
Per Share Data
EPS (TTM)
₹34.48
Book Value per Share
₹163.64
Revenue per Share
₹76.18
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| INDSWFTLAB | 12.0B | 4.00 | 0.84 | 21.35% | 41.86% | 1.69 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





